Skip to main content
main-content

Genitourinary cancers

News and opinion

08-10-2019 | Castration-sensitive prostate cancer | ESMO 2019 | Article

HRQoL data bolster positive survival findings from TITAN study

Adding apalutamide to androgen deprivation therapy does not result in increased levels of pain or fatigue, relative to placebo, nor does it negatively impact overall health-related quality of life, shows an analysis of data from the TITAN study.

08-10-2019 | Renal cell carcinoma | ESMO 2019 | News

JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.

08-10-2019 | Prostate cancer | News

Ultra-hypofractionated SBRT has low acute toxicity in localized prostate cancer

Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.

07-10-2019 | Urothelial cancer | ESMO 2019 | News

PFS boost with atezolizumab–chemotherapy in advanced urothelial carcinoma

Adding atezolizumab to chemotherapy significantly prolongs progression-free survival in the first-line advanced urothelial cancer setting, according to the IMvigor130 trial results presented at the ESMO Congress 2019.

30-09-2019 | Castration-resistant prostate cancer | ESMO 2019 | News

CARD results support cabazitaxel use in mCRPC

Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.

28-09-2019 | Castration-resistant prostate cancer | ESMO 2019 | News

Apalutamide may improve OS in men with nonmetastatic CRPC

An interim analysis from the SPARTAN trial points to an overall survival benefit with the use of apalutamide alongside androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer.

28-09-2019 | Prostate cancer | ESMO 2019 | News

STAMPEDE shows docetaxel benefit regardless of metastatic burden

Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.

26-09-2019 | Prostate cancer | News

Male infertility linked to increased prostate cancer risk

The risk for prostate cancer is 30–60% higher in men who father children through assisted reproduction than in those who conceive naturally, shows a nationwide study conducted in Sweden.

25-09-2019 | EMA | News

Avelumab indication extended in Europe to advanced RCC

Find out more here

25-09-2019 | Prostate cancer | News

IMPACT data support PSA screening in BRCA2 mutation carriers

Men with a BRCA2 mutation are more likely to be diagnosed with prostate cancer following annual prostate-specific antigen screening than men without the mutation, interim results from the multinational IMPACT study show.

24-09-2019 | Checkpoint blockade | News

Inflammatory arthritis persists post immune- checkpoint inhibitor therapy

Immune checkpoint inhibitor-induced inflammatory arthritis among patients with cancer may need long-term management by rheumatologists after cessation of treatment, but does not appear to affect cancer outcomes, say researchers.

23-09-2019 | FDA | News

Apalutamide approved by FDA for mCSPC

Read more on this decision here

20-09-2019 | Castration-resistant prostate cancer | News

Adding carboplatin to cabazitaxel benefits men with mCRPC

Phase I/II research published in The Lancet Oncology shows that combining cabazitaxel with carboplatin has the potential to prolong progression-free survival in men with metastatic castration-resistant prostate cancer.

17-09-2019 | Immunotherapy | Highlight | News

Notable number of patients taking immune checkpoint inhibitors hospitalized with irAEs

Patients receiving immune checkpoint inhibitor treatment have an increased risk for being hospitalized with immune-related adverse events, particularly if they are older or taking combination treatments, researchers report.

05-09-2019 | Testicular cancer | News

Brain metastases linked to poor survival in men with testicular germ cell tumors

Among men with testicular germ cell tumors, those with more than one extrapulmonary metastasis – particularly brain metastases – have the poorest survival, according to an analysis of data the US SEER database.

04-09-2019 | Prostate cancer | News

Pre-existing CVD linked to increased mortality with abiraterone, enzalutamide

Elderly patients with prostate cancer and pre-existing cardiovascular disease have a significantly higher short-term mortality risk following abiraterone acetate or enzalutamide treatment than those without CVD, US study findings indicate.

02-09-2019 | Cardiovascular disease | Highlight | News

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

21-08-2019 | Renal cell carcinoma | News

Long-term benefit of nivolumab plus ipilimumab shown in advanced RCC

Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.

19-08-2019 | FGFR inhibitors | Highlight | News

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

16-08-2019 | EMA | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

Image Credits